Black Diamond Therapeutics (BDTX) Retained Earnings: 2018-2021
Historic Retained Earnings for Black Diamond Therapeutics (BDTX) over the last 2 years, with Sep 2021 value amounting to -$218.0 million.
- Black Diamond Therapeutics' Retained Earnings fell 127.99% to -$218.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was -$218.0 million, marking a year-over-year decrease of 127.99%. This contributed to the annual value of -$118.2 million for FY2020, which is 131.95% down from last year.
- Latest data reveals that Black Diamond Therapeutics reported Retained Earnings of -$218.0 million as of Q3 2021, which was down 19.18% from -$182.9 million recorded in Q2 2021.
- Black Diamond Therapeutics' Retained Earnings' 5-year high stood at -$15.7 million during Q4 2018, with a 5-year trough of -$218.0 million in Q3 2021.
- Its 3-year average for Retained Earnings is -$119.4 million, with a median of -$106.9 million in 2020.
- Data for Black Diamond Therapeutics' Retained Earnings shows a maximum YoY slumped of 224.40% (in 2019) over the last 5 years.
- Black Diamond Therapeutics' Retained Earnings (Quarterly) stood at -$15.7 million in 2018, then tumbled by 224.40% to -$51.0 million in 2019, then plummeted by 131.95% to -$118.2 million in 2020, then crashed by 127.99% to -$218.0 million in 2021.
- Its Retained Earnings stands at -$218.0 million for Q3 2021, versus -$182.9 million for Q2 2021 and -$148.5 million for Q1 2021.